Ask AI
Risk Factors for Progression in PBC

CE / CME

Identifying Risk Factors for Disease Progression and Poor Response in PBC: Implications for First-line Therapy

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Released: March 30, 2026

Expiration: March 29, 2027

Activity

Progress
1 2 3
Course Completed

Baseline Risk Factors for PBC Progression/Treatment Failure

How do you determine who is at high risk and should be evaluated at 6 months rather than 12 months? When a person is diagnosed with PBC, these baseline risk factors associated with disease progression and the likelihood of UDCA treatment failure should be evaluated.1

I will review these individual risk factors and discuss how they can help determine how early to assess for response to UDCA.

Identifying Who Is at Greatest Risk for Disease Progression: Advanced Fibrosis by Biopsy

Although liver biopsy is not typically required to establish the diagnosis of PBC, historical studies evaluating disease progression relied on histologic data. These studies have helped clarify the relationship between fibrosis stage and clinical outcomes.11-13

Among people with PBC who undergo liver biopsy, the presence of advanced fibrosis at diagnosis, defined as stage III or IV fibrosis, has been associated with a significantly higher risk of liver transplant or death.14-16

These findings underscore the importance of evaluating fibrosis stage when evaluating a newly diagnosed person.14,15

Baseline Staging and Risk Assessment

However, liver biopsy is no longer routinely used to assess fibrosis in people with PBC. Instead, current recommendations are to use noninvasive, imaging-based techniques like transient elastography and magnetic resonance elastography to evaluate fibrosis stage and determine a person’s risk.1,16

Identifying Who Is at Greatest Risk for Disease Progression: Advanced Fibrosis by Imaging

Certain liver stiffness thresholds have been associated with a higher risk of disease progression. With transient elastography, a liver stiffness measurement of 10.2 kPa or greater has been associated with advanced fibrosis. People with values in this range have a higher likelihood of developing hepatic decompensation.17

Similarly, magnetic resonance elastography can identify advanced fibrosis using a threshold of 4.3 kPa. Values at or above this level are associated with an increased risk of hepatic decompensation.17

My approach is that every person with PBC undergoes imaging-based fibrosis assessment at baseline, and fibrosis is reassessed periodically during follow-up.

Additional Considerations for Risk Stratification in PBC

Baseline ALP and bilirubin levels have been associated with poor outcomes in patients with PBC, with the risk of liver transplantation or death increasing as these values increase above the ULN, regardless of treatment with UDCA. For ALP, the rise in risk is more gradual with increasing values of baseline ALP above the ULN, whereas for bilirubin, there is significantly higher risk for increasing baseline bilirubin values above the ULN.18

Although liver biopsy is not commonly performed for patients with PBC today, histologic findings can still provide useful prognostic information when available. For example, the presence of ductopenia on liver biopsy may indicate more advanced disease.19

Age at diagnosis is another important factor to consider when evaluating risk. Although studies have used different age thresholds, ranging from approximately 30 to older than 60 years, the broader concept remains consistent: people diagnosed at a younger age may require closer monitoring and more aggressive treatment goals.20-22[Hirshfield 2018]

Sex may also influence disease outcomes. Although PBC is a female-predominant disease, it can occur in men. Some studies suggest that men may experience more severe disease or may be diagnosed at a more advanced stage.19-21